MoonLake Immunotherapeutics (MLTX)

$5.97

+0.18 (+3.11%)
Rating:
Recommendation:
-
Symbol MLTX
Price $5.97
Beta 0.000
Volume Avg. 0.08M
Market Cap 220.446M
Shares () -
52 Week Range 4.25-15.19
1y Target Est -
DCF Unlevered MLTX DCF ->
DCF Levered MLTX LDCF ->
ROE -44.33% Strong Sell
ROA -2746756.89% Strong Sell
Operating Margin -
Debt / Equity 6.10% Neutral
P/E -
P/B 3.31 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Healthcare
Biotechnology
NASDAQ Global Market

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.